|
PDGFRA |
platelet derived growth factor receptor alpha |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Imatinib-resistant PDGFR mutants
- Sunitinib-resistant PDGFR mutants
- Regorafenib-resistant PDGFR mutants
- Sorafenib-resistant PDGFR mutants
- PDGFR mutants bind TKIs
|
- Becaplermin
- Imatinib
- Sunitinib
- XL820
- Olaratumab
- Pazopanib
- Midostaurin
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Foreskin keratinocyte (neonatal)
- Tivozanib
- Fostamatinib
- Erdafitinib
- Amuvatinib
- Ripretinib
|
|
|
PDGFRB |
platelet derived growth factor receptor beta |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Becaplermin
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- XL999
- XL820
- Pazopanib
- Midostaurin
- Regorafenib
- Nintedanib
- Polaprezinc
- Trapidil
- Foreskin fibroblast (neonatal)
- Tivozanib
- Fostamatinib
- Erdafitinib
- Pexidartinib
- Ripretinib
- Pralsetinib
|
|
|
PDK3 |
pyruvate dehydrogenase kinase 3 |
- Regulation of pyruvate dehydrogenase (PDH) complex
- Signaling by Retinoic Acid
|
- Radicicol
- Dihydrolipoic Acid
|
|
|
PDP1 |
pyruvate dehydrogenase phosphatase catalytic subunit 1 |
- Regulation of pyruvate dehydrogenase (PDH) complex
|
|
- Pyruvate dehydrogenase complex deficiency; X-linked Leigh syndrome
|
|
PELI1 |
pellino E3 ubiquitin protein ligase 1 |
- Regulation of necroptotic cell death
- Interleukin-1 signaling
- IRAK1 recruits IKK complex
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
|
|
PFKP |
phosphofructokinase, platelet |
|
|
|
|
PHKG1 |
phosphorylase kinase catalytic subunit gamma 1 |
- Glycogen breakdown (glycogenolysis)
- Glycogen breakdown (glycogenolysis)
|
|
|
|
PIK3C2A |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha |
- Synthesis of PIPs at the plasma membrane
- Synthesis of PIPs at the Golgi membrane
- Synthesis of PIPs at the early endosome membrane
- Synthesis of PIPs at the late endosome membrane
- Golgi Associated Vesicle Biogenesis
- Clathrin-mediated endocytosis
|
|
|
|
PIK3C2B |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta |
- Synthesis of PIPs at the plasma membrane
|
|
|
|
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- Extra-nuclear estrogen signaling
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK in cancer
- Signaling by LTK
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Co-stimulation by ICOS
|
- ATP
- Caffeine
- XL765
- Wortmannin
- Pilaralisib
- Alpelisib
- Copanlisib
|
|
|
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- GP1b-IX-V activation signalling
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK in cancer
- Signaling by LTK
- Co-stimulation by ICOS
|
- SF1126
- Enzastaurin
- Wortmannin
|
|
|
PIK3R2 |
phosphoinositide-3-kinase regulatory subunit 2 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- Downstream signal transduction
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK in cancer
- Signaling by LTK
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Co-stimulation by ICOS
|
|
|
|
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Extra-nuclear estrogen signaling
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Co-stimulation by ICOS
|
|
|
|
PIM1 |
Pim-1 proto-oncogene, serine/threonine kinase |
- Interleukin-4 and Interleukin-13 signaling
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 fusion proteins
|
- 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One
- Staurosporine
- LY-294002
- Imidazole
- (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One
- Bisindolylmaleimide I
- Quercetin
- Phosphoaminophosphonic Acid-Adenylate Ester
- Dexfosfoserine
- S,S-(2-Hydroxyethyl)Thiocysteine
- IMIDAZOPYRIDAZIN 1
- 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one
- (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
- N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine
- (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile
- (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
- Tricetin
- 6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
- 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine
- N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine
- 2,3-diphenyl-1H-indole-7-carboxylic acid
- Fostamatinib
|
|
|
PIN4 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 4 |
|
|
|
|
PITPNA |
phosphatidylinositol transfer protein alpha |
- Role of second messengers in netrin-1 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
- 1,2-diacyl-sn-glycero-3-phosphoinositol
- (Z,Z)-4-Hydroxy-N,N,N-Trimethyl-10-Oxo-7-[(1-Oxo-9-Octadecenyl)Oxy]-3,5,9-Trioxa-4-Phosphaheptacos-18-En-1-Aminium-4-Oxide
|
|
|
PKIA |
cAMP-dependent protein kinase inhibitor alpha |
|
- 3,5-Diiodotyrosine
- Hydroxyfasudil
- (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
- (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
- (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
- (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
- N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
- (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
- (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- H-89
- 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
- N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
- 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- 3-pyridin-4-yl-1H-indazole
- 5-benzyl-1,3-thiazol-2-amine
- 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
- Fasudil
- Myristic acid
- A-674563
- 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
- Y-27632
|
|
|
PLCG1 |
phospholipase C gamma 1 |
- ISG15 antiviral mechanism
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- PLC-gamma1 signalling
- Synthesis of IP3 and IP4 in the cytosol
- Downstream signal transduction
- Signaling by ALK
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- Role of phospholipids in phagocytosis
- PECAM1 interactions
- EGFR interacts with phospholipase C-gamma
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Role of second messengers in netrin-1 signaling
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated cell proliferation
- Constitutive Signaling by EGFRvIII
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RET signaling
- Activated NTRK2 signals through PLCG1
- Activated NTRK2 signals through PLCG1
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through PLCG1
- FCGR3A-mediated IL10 synthesis
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by ALK fusions and activated point mutants
|
|
|
|
PLCG2 |
phospholipase C gamma 2 |
- GPVI-mediated activation cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Synthesis of IP3 and IP4 in the cytosol
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CLEC7A (Dectin-1) signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Erythropoietin activates Phospholipase C gamma (PLCG)
- FCGR3A-mediated IL10 synthesis
- Potential therapeutics for SARS
- Signaling by CSF1 (M-CSF) in myeloid cells
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
|
PLD1 |
phospholipase D1 |
- Synthesis of PG
- Synthesis of PA
- Role of phospholipids in phagocytosis
- Neutrophil degranulation
- RHOA GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RHOG GTPase cycle
|
- Choline
- LAX-101
- Choline salicylate
|
|